BlinkLab Limited (ASX:BB1) disclosed that clinical data from its autism and ADHD research programs were presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience, held in Washington, D.C. from 14 to 18 November 2026, with the company noting the event draws more than 30,000 attendees from approximately 80 countries.

Key Points

  • Two data presentations delivered at Neuroscience 2026 in Washington, D.C., covering autism and ADHD research programs.
  • The autism presentation showed how reflex-based and spontaneous sensorimotor biomarkers, captured in a 15-minute smartphone assessment, can distinguish autistic from neurotypical children.
  • The ADHD presentation showed smartphone-derived movement biomarkers were correlated with clinician-rated hyperactivity, impulsivity, and inattention.
  • More than 600 children were assessed across Morocco and the Netherlands in the underlying research cohorts.
  • Submission of BlinkLab Dx1 to the U.S. Food and Drug Administration is expected in Q1 2027, with the U.S. pivotal study remaining the company's stated priority.

Two Presentations at the Society for Neuroscience Annual Meeting

The first presentation, titled "Multivariate Neurobehavioral Measures as Objective Markers of Autism," was delivered by Kayleigh Gultig, Clinical Research Associate at BlinkLab, and examined how reflex-based and spontaneous sensorimotor biomarkers captured via smartphone can be combined to distinguish autistic from neurotypical children. The second presentation, titled "Characterizing Sensory Processing in Children with ADHD Using Smartphone-Based Measurements of Acoustic Startle and Prepulse Inhibition," was delivered by Lotte Roggeveen, Clinical Research Manager at BlinkLab, and focused on smartphone-derived movement markers correlated with clinician-rated ADHD symptoms.

Academic Collaborations and Research Scale

According to the filing, the autism data was collected in collaboration with the Mohammed V Foundation for Solidarity in Morocco, while the ADHD data was collected with Mental Care Group in the Netherlands. The broader research involved collaborations with Erasmus MC and Princeton University. BlinkLab disclosed that more than 600 children were assessed across Morocco and the Netherlands in clinical and community settings. The company stated that BlinkLab researchers are listed as authors on both presentations, combining neuroscience, computer vision, and machine learning.

Dx1 Regulatory Program and FDA Submission Timeline

BlinkLab stated that its U.S. pivotal study of BlinkLab Dx1 remains the company's priority. The company disclosed that submission to the U.S. Food and Drug Administration is expected in Q1 2027. BlinkLab Dx1 is described in the filing as an autism diagnostic aid for clinicians that uses smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures. The filing noted that the company was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism.